Last $707.20 MXN
Change Today -12.70 / -1.76%
Volume 800.0
As of 10:39 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

Petach Tikva, 49131

Israel

Phone: 972 3 926 7267

Fax: 972 3 923 4050

asl. ProAir (albuterol HFA), which the company sells only in the United States, is a short-acting beta-agonist (SABA) for the treatment of bronchial spasms linked to asthma or COPD and exercise-induced bronchospasm. Qvar (beclomethasone diproprionate HFA) is an inhaled corticosteroid for long-term control of chronic bronchial asthma. Women’s Health Products The company’s women’s health product line includes its specialty women’s health products such as Paragard, Plan B One-Step, Zoely, Enjuvia. Other Activities In addition to its generic and specialty medicines segments, the company has other activities, primarily PGT Healthcare, its OTC joint venture with P&G, distribution services, primarily in Israel and Hungary and sales of medical devices. Others The company has other activities, primarily PGT Healthcare, its OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. Other sources of revenue include sales of third party products for which the company acts as distributors (mostly in Israel and Hungary) and medical products, as well as miscellaneous items. Specialty Medicines Research and Development Expenses Research and development expenses relating to the company’s specialty medicines in 2013 were $909 million. Research and Development Laquinimod is a once-daily, orally administered immunomodulatory compound being developed for treatment of relapsing-remitting multiple sclerosis. The company acquired the exclusive rights to develop, register, manufacture and commercialize laquinimod worldwide from Active Biotech. Laquinimod is in Phase II evaluation for Crohn’s Disease. TV-7820 (pridopidine) is an oral small molecule dopamine stabilizer being developed for the symptomatic treatment of motor disorders (including Huntington’s disease, or HD), which the company licensed from Neurosearch A/S in late 2012. Phase II clinical development is planned to begin in early 2014. Pridopidine is protected by patents expiring in 2020 worldwide. TV-45070 (XEN 402) is a small molecule intended to treat pain locally at its source through blocking of Nav1.7 and Nav1.8 sodium channels, which are found in sensory nerve endings that can increase in chronic painful conditions. TV-45070 was licensed from Xenon Pharmaceuticals Inc. in December 2012. TV-45070 has been studied in human subjects in both oral and topical forms in neuropathic and inflammatory diseases. TV-45070 is in Phase II development for a variety of pain-related, neuropathic and inflammatory disorders. TV-45070 is protected by patents expiring in 2026 in Europe and in 2028 in the United States. Respiratory The primary area of focus of the company’s respiratory R&D is the development of products that are based on its proprietary delivery systems, which include an advanced breath-actuated inhaler (BAI); Spiromax/Airmax, a novel inhalation-driven multi-dose powder inhaler (MDPI); Teva MicroDose, a nebulization device; and Steri-Neb, its advanced sterile formulations for nebulizers. The company’s proprietary MDPI device (Spiromax) is protected by patents expiring in 2021. DuoResp Spiromax is a combination of budesonide and formoterol utilizing the company’s proprietary Spiromax device. QVAR BAI (beclomethasone) is an oral aerosol corticosteroid in development for the treatment of asthma delivered using the company’s advanced breath-actuated inhaler. The Phase III clinical program was initiated in December 2013. Albuterol MDPI is a dry-powder inhaler formulation of albuterol in the company’s multi-dose powder inhaler device that is designed to be an improvement to its ProAir HFA. QNASL (beclomethasone HFA Nasal) is a nasal aerosol corticosteroid indicated for the treatment of adult and adolescent perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR). The company is conducting a Phase III program to gain a pediatric indication. Reslizumab is an investigational humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). IL-5 has been shown to play a crucial role in the maturation, growth and chemotaxis (movement) of eosinophils, inflammatory white blo

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $707.20 MXN -12.70

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEVAN.
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
No financial data is available for TEVAN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.